Navigation Links
FirstMark Scientific Board of Advisors Meet to Discuss New Clinical Studies for PREvent
Date:7/19/2012

SAN DIEGO, July 19, 2012 /PRNewswire-iReach/ -- FirstMark, provider of the groundbreaking cardiovascular blood test PREvent, announced the meeting of the Scientific Advisory Board, held today on July 19, 2012. The July meeting focused on the selection and planning of future clinical validation studies, designed according to the following priorities: an independent clinical validation of the test for coronary artery disease patients, expansion of clinical utilization of the test to a more generalized population, validation of improved outcomes with PREvent testing for medical management optimization, and the impact of the test on health economics.

"Each member of our prestigious Scientific Advisory Board has made extraordinary contributions to cardiovascular medicine and research. We are honored to have their expertise as we move into this next phase for PREvent.  It's an exciting time for FirstMark, now that PREvent has gained momentum for clinical adoption, especially among primary care physicians and internists" says Thomas Silberg, President and CEO of GenWay Biotech. "PREvent's launch was based on the remarkable data resulting from the 4-year, 3,414 cohort study at Emory University. We look forward to implementing plans based on the advice of our scientific advisors for the selected future trials that will uncover additional benefits of PREvent for coronary artery disease patients, and expand utility of the test to other patient populations. Most importantly, the future clinical validation studies are designed to provide evidence that PREvent can improve outcomes for patients tested with PREvent, and have an impact on overall health economics of coronary artery disease patients' management."

The FirstMark Scientific Advisory Board is comprised of prominent cardiologist and research scientists including:

George A. Beller, MD, MACC
Cardiologist, University of Virginia Health System
Past President of the American College of Cardiology
Past President of the Association of University Cardiologists
Past President of the Association of Professors of Cardiology

Stephen Epstein, MD
Executive Director of the Cardiovascular Research Institute (CRI), MedStar Health Research Institute
Clinical Professor of Medicine at the Georgetown University School of Medicine
Former Chief of the Cardiology Branch of the NHLBI at the National Institutes of Health in Bethesda, MD

Arshed Quyyumi, MD, FACC, FRCP
Tenured Professor of Medicine, Division of Cardiology, Emory University School of Medicine,
Co-Director, Emory Clinical Cardiovascular Research Institute

Prediman K. Shah, MD, FACC, FACP, FRCP
Director, Division of Cardiology at Cedars-Sinai Medical Center
Director, Oppenheimer Atherosclerosis Research Center at Cedars-Sinai Medical Center
Shapell and Webb Family Chair in Clinical Cardiology
Professor, Cedars-Sinai Professorial Series

Sergey Sikora, PhD, MBA
Sr. Vice President,  FirstMark

Robert Wilensky, MD
Professor of Medicine at the Hospital of the University of Pennsylvania
Director, Interventional Cardiology Research

Peter Wilson, MD
Professor of Medicine, Emory Clinical Cardiovascular Research Institute
Professor of Public Health at the Rollins School of Public Health
Director of Epidemiology and Genomic Medicine, Atlanta VA Medical Center
Co-Developer and former Director of Laboratories at the Framingham Heart Study, National Heart, Lung, and Blood Institute, Framingham, Mass

For more information about FirstMark PREvent and the Scientific Advisory Board, visit FirstMarkPREvent.com

FirstMark PREvent
PREvent is the first and only multiple biomarker blood test on the market that predicts near term (2-3 years) risk of myocardial infarction (MI) in patients with suspected or confirmed, insignificant or significant coronary artery disease (CAD).  PREvent identifies CAD patients in the top 4% at highest risk, and the next 17% at moderate risk of MI. The data showed an annual average of 16% of CAD patients with all three biomarkers elevated experienced a myocardial infarction or death, compared to only 2% of CAD patients with all biomarkers normal. It also reclassifies 42% of CAD patients from high to low risk, or low to high risk.

About FirstMark
FirstMark is Division of GenWay Biotech. FirstMark is focused on the development and commercialization of non-invasive diagnostic and health monitoring tests for unmet clinical needs. Headquarters are located in the heart of San Diego's biotech community in the Sorrento Valley/Mesa area.

6777 Nancy Ridge Drive, San Diego, CA 92121     |     P: 858.458.0866    |     F: 858.458.0833

Media Contact: Deborah Moore FirstMark, 858-458-0866 x 113, dmoore@thefirstmark.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE FirstMark
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. FirstMark Exhibiting and Presenting at the San Diego Academy of Family Physicians 55th Annual Postgraduate Symposium
2. FirstMark Welcomes Renowned Cardiologist and Researcher Dr. Prediman K. Shah to Scientific Advisory Board
3. FirstMark Welcomes Renowned Cardiologist and Researcher Dr. Prediman K. Shah to Scientific Advisor Board
4. FirstMark Exhibiting at the Inaugural Atlanta Clinical Cardiology Update
5. FirstMark Announces New Hire Jay Houtman as Southeast Regional Sales Manager
6. New model in scientific publishing: GigaScience combines article and data publication
7. WALTHAM® demonstrates commitment to scientific dialogue and exchange at international human animal interaction conference
8. CRN assesses current state of scientific research for nutritional supplements
9. Scientific meeting at Virginia Tech will make more than $2 million economic impact
10. NTU researchers study little mighty creature for scientific breakthrough
11. Womens scientific achievements often overlooked and undervalued
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
(Date:4/19/2016)... 20, 2016 The new GEZE ... compact web-based "all-in-one" system solution for all door components. ... or the door interface with integration authorization management system, ... systems. The minimal dimensions of the access control and ... building installations offer considerable freedom of design with regard ...
(Date:3/31/2016)...   LegacyXChange, Inc. ... LegacyXChange is excited to release its first ... be launched online site for trading 100% guaranteed authentic ... also provide potential shareholders a sense of the value ... industry that is notorious for fraud. The video is ...
Breaking Biology News(10 mins):
(Date:5/26/2016)... -- Despite the volatility that continues to envelop ... pre-market research on ActiveWallSt.com directs the investor community,s focus on ... RDUS ), Cerus Corp. (NASDAQ: CERS ), Arrowhead ... Therapeutics Inc. (NASDAQ: FPRX ). Register with us ... http://www.activewallst.com/ On Wednesday, shares in ...
(Date:5/26/2016)... ... May 26, 2016 , ... FireflySci has been ... leading laboratories all over the globe. Their cute firefly logo has been spreading ... cuvettes, FireflySci makes spectrophotometer calibration standards that never require recalibration. These revolutionary ...
(Date:5/25/2016)... , ... May 25, 2016 , ... ... a variety of fracture-specific plating options designed to address fractures of the distal ... fixation solutions. , The Acumed Ankle Plating System 3 is composed of seven ...
(Date:5/25/2016)... ... , ... Scientists at the University of Athens say they have evidence that ... the research that could lead to one good one. Surviving Mesothelioma has just posted ... , The team evaluated 98 mesothelioma patients who got a second kind ...
Breaking Biology Technology: